Literature DB >> 1732007

Transforming growth factor beta inhibits megakaryocyte growth and endomitosis.

D J Kuter1, D M Gminski, R D Rosenberg.   

Abstract

Using a rat bone marrow culture system, the effect of transforming growth factor beta 1 (TGF beta 1) on megakaryocyte growth and endoreduplication has been studied. Purified human platelet TGF beta 1 inhibited the number of megakaryocytes that appeared in culture at a half-maximal concentration of 0.66 +/- 0.21 ng/mL and inhibited megakaryocyte endoreduplication at a half-maximal concentration of 0.14 +/- 0.08 ng/mL. Under identical conditions, growth of erythroid precursors was half-maximally inhibited at a concentration of 0.125 ng/mL while myeloid growth was not inhibited at concentrations of TGF beta 1 up to 25 ng/mL. These profound inhibitory effects on megakaryocyte growth and endomitosis suggested that TGF beta might play a role in megakaryocytopoiesis. Therefore, we explored the effect of TGF beta in three different experimental situations by using a neutralizing antibody to TGF beta: (1) Serum but not plasma was found to inhibit the number and ploidy of megakaryocytes that grew in vitro. This inhibitory activity was completely neutralized by antibody to TGF beta or on treatment with dithiothreitol. (2) Plasma from thrombocytotic rats was observed to decrease megakaryocyte ploidy on culture but this effect was not prevented by the addition of antibody to TGF beta. (3) Plasma from thrombocytopenic but not normal rats increased megakaryocyte ploidy on culture. Addition of antibody to TGF beta did not alter these results. Therefore, TGF beta is a potent inhibitor of the number and ploidy of megakaryocytes and accounts for all the inhibition seen when megakaryocytes are cultured in serum. However, the differences in effect on megakaryocyte growth that we observe between normal, thrombocytopenic, and thrombocytotic plasmas are not due to variations in the amount of TGF beta. Furthermore, our results show that release of TGF beta from megakaryocytes during culture does not act as an autocrine regulator of megakaryocyte ploidy in vitro.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732007

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.

Authors:  Muna Iraqi; Jose Perdomo; Feng Yan; Philip Y-I Choi; Beng H Chong
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

2.  Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia.

Authors:  Haiyu Zhang; Bing M Zhang; Xiangqian Guo; Liwen Xu; Xiaoqing You; Robert B West; James B Bussel; James L Zehnder
Journal:  Haematologica       Date:  2019-07-11       Impact factor: 9.941

3.  Cytokine production by a megakaryocytic cell line.

Authors:  B Sandrock; K M Hudson; D E Williams; M A Lieberman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

Review 4.  Megakaryocyte ontogeny: Clinical and molecular significance.

Authors:  Kamaleldin E Elagib; Ashton T Brock; Adam N Goldfarb
Journal:  Exp Hematol       Date:  2018-03-02       Impact factor: 3.084

Review 5.  Megakaryocytes as immune cells.

Authors:  Pierre Cunin; Peter A Nigrovic
Journal:  J Leukoc Biol       Date:  2019-01-15       Impact factor: 4.962

6.  Expression of plasma membrane receptor genes during megakaryocyte development.

Authors:  Sijie Sun; Wenjing Wang; Yvette Latchman; Dayong Gao; Bruce Aronow; Jo-Anna Reems
Journal:  Physiol Genomics       Date:  2013-01-15       Impact factor: 3.107

7.  Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.

Authors:  Waleed Ghanima; Julia Turbiner Geyer; Christina S Lee; Leonardo Boiocchi; Allison A Imahiyerobo; Attilio Orazi; James B Bussel
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

8.  The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production.

Authors:  D J Kuter; D L Beeler; R D Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

Review 9.  Molecular control of megakaryopoiesis and thrombopoiesis.

Authors:  Itaru Matsumura; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

10.  Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling.

Authors:  Tony E Walshe; Vandana S Dole; Arindel S R Maharaj; Ian S Patten; Denisa D Wagner; Patricia A D'Amore
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-05-21       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.